Details

Autor(en) / Beteiligte

• Thomas, Stephen J
• Moreira, Edson D
• Kitchin, Nicholas
• Absalon, Judith
• Gurtman, Alejandra
• Lockhart, Stephen
• Perez, John L
• Marc, Gonzalo Pérez
• Polack, Fernando P
• Zerbini, Cristiano
• Bailey, Ruth
• Swanson, Kena A
• Xu, Xia
• Roychoudhury, Satrajit
• Koury, Kenneth
• Bouguermouh, Salim
• Kalina, Warren V
• Cooper, David
• Frenck, Robert W
• Hammitt, Laura L
• Türeci, Özlem
• Nell, Haylene
• Schaefer, Axel
• Ünal, Serhat
• Yang, Qi
• Liberator, Paul
• Tresnan, Dina B
• Mather, Susan
• Dormitzer, Philip R
• Şahin, Uğur
• Gruber, William C
• Jansen, Kathrin U

Titel

Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older

Ist Teil von

• Future virology, 2022-12, Vol.17 (12), p.849-862

Ort / Verlag

Future Medicine Ltd

Erscheinungsjahr

2022

Link zum Volltext

Beschreibungen/Notizen

• What is this summary about? This is a summary of an article about part of a clinical study for the BNT162b2 COVID-19 vaccine, also called the Pfizer-BioNTech vaccine. The article was published in the New England Journal of Medicine in September 2021. The part of the study described in the article began in July 2020 and is ongoing. This means that the final results may be different from the results included in this summary. What happened in this study? The participants in this study received 2 injections of either the BNT162b2 vaccine or a placebo, 21 days apart. The placebo looked like the BNT162b2 vaccine but had no active vaccine in it. None of the trial participants or study teams knew who received vaccine or placebo. What were the results? Most of the reactions to the injections were mild or moderate and lasted for a short period of time. The most common reactions were pain at the injection site, extreme tiredness (fatigue), and headache. These reactions usually happened in the first 7 days after receiving a vaccine dose. A small number of participants had severe reactions to the vaccine. Compared to participants who received the placebo, participants who received the BNT162b2 vaccine were much less likely to become ill if they were infected with the virus that causes COVID-19. The vaccine also had very good efficacy at preventing severe COVID-19. Participants in South Africa who received the BNT162b2 vaccine were less likely to become ill after infection with the beta variant of the virus compared to participants who received the placebo. The beta variant was very common in South Africa when the study was taking place. Clinical Trial Registration: NCT04368728 ( ClinicalTrials.gov )